STRO-002-GM1: Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers (clinicaltrials.gov) - Jun 11, 2024 - P1 | N=160 | Active, not recruiting | Sponsor: Sutro Biopharma, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Aug 2024 ➔ Nov 2024
Enrollment closed • Metastases • Trial completion date • Endometrial Cancer • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor
|